Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...

AstraZeneca PLC closed 20.63% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

The overhaul was nicknamed Project Arden as a nod to the Elizabeth Arden beauty salon, best known at the time for its ...

Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-risk sexual ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Challenging the minister earlier over AstraZeneca and its reported exit from the London market, Tory shadow Treasury minister ...

Turbine, the company virtualizing experiments with AI to accelerate discovery and clinical decisions, today announced the addition of Andrew Pape, PhD and Gregory Vladimer, PhD to its Scientific ...

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data ...

Review the current AstraZeneca PLC ADR (AZN:XNAS) dividend yield and history to decide if AZN is the best investment for you.

Stay up to date on how AstraZeneca PLC ADR (AZN:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.